Investors

Key press releases

26 Jun 2025
16:30 E.S.T.

Corporate

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

21 May 2025
16:30 E.S.T.

Corporate

Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025

12 May 2025
16:30 E.S.T.

Finance

Cellectis Reports Financial Results for the First Quarter 2025

Key upcoming events

15 Jul 2025 ‐ 17 Jul 2025

4th Annual Process Development for Cell Therapies Summit

Learn more

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$1.5800

-0.0700 (-4.2424%)

Prev. close: 1.6500
Volume: 37,406
High: 1.6500
Capitalization: 113.908M

€1.3980

+0.0220 (1.5988%)

Prev. close: 1.3760
Volume: 30,352
High: 1.3980
Capitalization: 100.787M

See stock information

Covering research analysts

Barclays - Gena Wang

Bryan Garnier - Oscar Haffen-Lamm

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Chief Financial Officer & Chief Business Officer

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89